Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 20/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2563601 | 0.97 | PTGDR (1.00) | PTGDR | |
| SCHEMBL29832387 | 0.97 | PTGDR (1.00) | PTGDR | |
| Hydrochloric Acid SCHEMBL4501077 | 0.96 | PTGDR (0.98) | PTGDR | |
| SCHEMBL2470868 | 0.90 | PTGDR (0.79) | PTGDR | |
| SCHEMBL4500130 | 0.90 | PTGDR (0.87) | PTGDR | |
| SCHEMBL4142625 | 0.89 | PTGDR (0.86) | PTGDR | |
| SCHEMBL4142580 | 0.89 | PTGDR (0.85) | PTGDR | |
| SCHEMBL4489706 | 0.88 | PTGDR (0.84) | PTGDR | |
| SCHEMBL4641925 | 0.88 | PTGDR (0.83) | PTGDR | |
| SCHEMBL4489727 | 0.87 | PTGDR (1.00) | PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2653193-A1 | Method for treating macular degeneration | SANOFI (FR) | 2013-10-23 | — | — | EP | claimed |
| EP-2370077-A2 | METHOD FOR TREATING MACULAR DEGENERATION | SANOFI (FR) | 2011-10-05 | — | — | EP | claimed |
| WO-2010080563-A2 | METHOD FOR TREATING MACULAR DEGENERATION | SANOFI-AVENTIS (FR) | 2010-07-15 | — | — | WO | claimed |
| EP-2653193-A1 | Method for treating macular degeneration | SANOFI (FR) | 2013-10-23 | — | — | EP | disclosed |
| EP-2170837-B1 | PROCESS FOR PREPARING 2-(3-{6-[2-(2,4-DICHLOROPHENYL)-ETHYLAMINO]-2-METHOXYPYRIMIDIN-4-YL)-PHENYL)-2-METHYLPROPIONIC ACID | SANOFI SA (FR) | 2011-11-02 | — | — | EP | disclosed |
| EP-2370077-A2 | METHOD FOR TREATING MACULAR DEGENERATION | SANOFI (FR) | 2011-10-05 | — | — | EP | disclosed |
| US-20100184979-A1 | NEW PROCESS FOR PREPARING 2-(3--PHENYL)-2-METHYLPROPRIONIC ACID | SANOFI-AVENTIS (FR) | 2010-07-22 | — | — | US | disclosed |
| WO-2010080563-A2 | METHOD FOR TREATING MACULAR DEGENERATION | SANOFI-AVENTIS (FR) | 2010-07-15 | — | — | WO | disclosed |
| EP-2170837-A2 | PROCESS FOR PREPARING 2-(3-{6-[2-(2,4-DICHLOROPHENYL)-ETHYLAMINO]-2-METHOXYPYRIMIDIN-4-YL)-PHENYL)-2-METHYLPROPIONIC ACID | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009006086-A2 | A NEW PROCESS FOR PREPARING 2-(3-{6-[2-(2,4-DICHLOROPHENYL)-ETHYLAMINO]-2-METHOXYPYRIMIDIN-4-YL}-PHENYL)- 2-METHYLPROPIONIC ACID | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184979-A1 | NEW PROCESS FOR PREPARING 2-(3--PHENYL)-2-METHYLPROPRIONIC ACID | DCPS, HPD, PAH | PTGDR 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.